Lixte Biotechnology Holdings Stock Analysis
| LIXTW Stock | USD 0.03 0 2.86% |
Lixte Biotechnology Holdings is overvalued with Real Value of 0.0281 and Hype Value of 0.03. The main objective of Lixte Biotechnology stock analysis is to determine its intrinsic value, which is an estimate of what Lixte Biotechnology Holdings is worth, separate from its market price. There are two main types of Lixte Biotechnology's stock analysis: fundamental analysis and technical analysis.
The Lixte Biotechnology stock is traded in the USA on NASDAQ Exchange, with the market opening at 09:30:00 and closing at 16:00:00 every Mon,Tue,Wed,Thu,Fri except for officially observed holidays in the USA. Lixte Biotechnology is usually not traded on Thanksgiving Day, Christmas Day, New Year 's Day, National Mourning Day, Dr . Martin Luther King Jr 's Birthday, Washington 's Birthday, Good Friday, Memorial Day, Juneteenth Holiday, Independence Day, Labour Day. Lixte Stock trading window is adjusted to America/New York timezone.
Lixte |
Lixte Stock Analysis Notes
The company had not issued any dividends in recent years. Lixte Biotechnology Holdings, Inc. operates as a drug discovery company that uses biomarker technology to identify enzyme targets related with serious common diseases and designs novel compounds to attack those targets. The company was founded in 2005 and is based in East Setauket, New York. Lixte Biotechnology is traded on NASDAQ Exchange in the United States. To find out more about Lixte Biotechnology Holdings contact Bastiaan MSc at 631 830 7092 or learn more at https://lixte.com.Lixte Biotechnology Investment Alerts
| Lixte Biotechnology is way too risky over 90 days horizon | |
| Lixte Biotechnology has some characteristics of a very speculative penny stock | |
| Lixte Biotechnology appears to be risky and price may revert if volatility continues | |
| Lixte Biotechnology has high likelihood to experience some financial distress in the next 2 years | |
| Net Loss for the year was (3.59 M) with profit before overhead, payroll, taxes, and interest of 0. | |
| Lixte Biotechnology Holdings has accumulated about 1.08 M in cash with (3.16 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 0.1, which can makes it an attractive takeover target, given it will continue generating positive cash flow. | |
| Lixte Biotechnology has a poor financial position based on the latest SEC disclosures |
Lixte Market Capitalization
The company currently falls under 'Micro-Cap' category with a current market capitalization of 39.49 M.Technical Drivers
As of the 28th of March, Lixte Biotechnology secures the Mean Deviation of 9.75, risk adjusted performance of 0.0996, and Downside Deviation of 23.61. In connection with fundamental indicators, the technical analysis model lets you check existing technical drivers of Lixte Biotechnology, as well as the relationship between them. Please verify Lixte Biotechnology standard deviation, as well as the relationship between the value at risk and kurtosis to decide if Lixte Biotechnology Holdings is priced some-what accurately, providing market reflects its recent price of 0.034 per share. As Lixte Biotechnology appears to be a penny stock we also strongly suggest to check its total risk alpha numbers.Lixte Biotechnology Price Movement Analysis
The output start index for this execution was nineteen with a total number of output elements of fourty-two. The Bollinger Bands is very popular indicator that was developed by John Bollinger. It consist of three lines. Lixte Biotechnology middle band is a simple moving average of its typical price. The upper and lower bands are (N) standard deviations above and below the middle band. The bands widen and narrow when the volatility of the price is higher or lower, respectively. The upper and lower bands can also be interpreted as price targets for Lixte Biotechnology. When the price bounces off of the lower band and crosses the middle band, then the upper band becomes the price target.
Lixte Biotechnology Insider Trading Activities
Some recent studies suggest that insider trading raises the cost of capital for securities issuers and decreases overall economic growth. Trading by specific Lixte Biotechnology insiders, such as employees or executives, is commonly permitted as long as it does not rely on Lixte Biotechnology's material information that is not in the public domain. Local jurisdictions usually require such trading to be reported in order to monitor insider transactions. In many U.S. states, trading conducted by corporate officers, key employees, directors, or significant shareholders must be reported to the regulator or publicly disclosed, usually within a few business days of the trade. In these cases Lixte Biotechnology insiders are required to file a Form 4 with the U.S. Securities and Exchange Commission (SEC) when buying or selling shares of their own companies.
Forman Eric over six months ago Acquisition by Forman Eric of 2500 shares of Lixte Biotechnology at 0.5599 subject to Rule 16b-3 | ||
Robert Weingarten over six months ago Acquisition by Robert Weingarten of 200000 shares of Lixte Biotechnology subject to Rule 16b-3 | ||
Bernards Rene over six months ago Acquisition by Bernards Rene of 10000 shares of Lixte Biotechnology at 0.61 subject to Rule 16b-3 | ||
Bernards Rene over six months ago Acquisition by Bernards Rene of 5527 shares of Lixte Biotechnology at 2.51 subject to Rule 16b-3 |
Lixte Biotechnology Predictive Daily Indicators
Lixte Biotechnology intraday indicators are useful technical analysis tools used by many experienced traders. Just like the conventional technical analysis, daily indicators help intraday investors to analyze the price movement with the timing of Lixte Biotechnology stock daily movement. By combining multiple daily indicators into a single trading strategy, you can limit your risk while still earning strong returns on your managed positions.
| Daily Balance Of Power | (9,223,372,036,855) | |||
| Rate Of Daily Change | 0.97 | |||
| Day Median Price | 0.034 | |||
| Day Typical Price | 0.034 | |||
| Price Action Indicator | (0.0005) | |||
| Period Momentum Indicator | (0) | |||
| Relative Strength Index | 47.45 |
Lixte Biotechnology Forecast Models
Lixte Biotechnology's time-series forecasting models are one of many Lixte Biotechnology's stock analysis techniques aimed at predicting future share value based on previously observed values. Time-series forecasting models ae widely used for non-stationary data. Non-stationary data are called the data whose statistical properties e.g. the mean and standard deviation are not constant over time but instead, these metrics vary over time. These non-stationary Lixte Biotechnology's historical data is usually called time-series. Some empirical experimentation suggests that the statistical forecasting models outperform the models based exclusively on fundamental analysis to predict the direction of the market movement and maximize returns from investment trading.About Lixte Stock Analysis
Stock analysis is the technique used by a trader or investor to examine and evaluate how Lixte Biotechnology prices is reacting to, or reflecting on a current market direction and economic conditions. It can be used to make informed decisions about market timing, and when buying or selling Lixte shares will generate the highest return on investment. We also built our stock analysis module to help investors to gain an insight into the world economy as a whole, the stock market, thematic ideas. a specific sector, or an individual Stock such as Lixte Biotechnology. By using and applying Lixte Stock analysis, traders can create a robust methodology for identifying Lixte entry and exit points for their positions.
Lixte Biotechnology Holdings, Inc. operates as a drug discovery company that uses biomarker technology to identify enzyme targets related with serious common diseases and designs novel compounds to attack those targets. The company was founded in 2005 and is based in East Setauket, New York. Lixte Biotechnology is traded on NASDAQ Exchange in the United States.
Be your own money manager
As an investor, your ultimate goal is to build wealth. Optimizing your investment portfolio is an essential element in this goal. Using our stock analysis tools, you can find out how much better you can do when adding Lixte Biotechnology to your portfolios without increasing risk or reducing expected return.Did you try this?
Run Premium Stories Now
Premium StoriesFollow Macroaxis premium stories from verified contributors across different equity types, categories and coverage scope |
| All Next | Launch Module |
Additional Tools for Lixte Stock Analysis
When running Lixte Biotechnology's price analysis, check to measure Lixte Biotechnology's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Lixte Biotechnology is operating at the current time. Most of Lixte Biotechnology's value examination focuses on studying past and present price action to predict the probability of Lixte Biotechnology's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Lixte Biotechnology's price. Additionally, you may evaluate how the addition of Lixte Biotechnology to your portfolios can decrease your overall portfolio volatility.